Nature Medicine | Spoonful of Medicine

Competition intensifies over market for DNA-based prenatal tests

Prenatal DNA testing has been a fiercely contested market of late. Yet another competitor entered the fray last week when Natera, a startup based in San Carlos, California, announced the 1 March launch date of a commercial test that can detect chromosomal abnormalities in the developing fetus from just a drop of an expectant mother’s blood—and with a sensitivity on par of that of more invasive techniques such as amniocentesis and chorionic villus sampling, both of which carry an elevated risk of miscarriage. 


Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.